Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors
Alimentary Pharmacology & Therapeutics · 2023-04 · 57 (7) · 792-799
DOI: 10.1111/apt.17352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 28.12.2022. Verfasst von Franck Carbonnel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service de Gastroentérologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Dual blockade of BRAF and MEK kinases is a standard of care for metastatic V600E/K BRAF mutant melanoma. This study reports the first systematic description of colitis due to BRAF and MEK inhibitors.
Methods
We studied consecutive patients with melanoma, treated with BRAF and MEK inhibitors, who had colitis requiring hospitalisation. Electronic files were studied; endoscopic biopsies and colectomy specimens were read centrally.
Results
Between January 2021 and March 2022, nine women and one man, aged 50–90 years, were studied. Nine patients received encorafenib and binimetinib; one patient received dabrafenib and trametinib. The main symptoms were diarrhoea, haematochezia, abdominal pain and intestinal obstruction. Blood tests showed anaemia, increased CRP and low serum albumin levels in most patients. All patients had ulcerations of the right colon with (2/10) or without (8/10) stenosis of the ileocecal valve, and 4/10 patients also had ulcerations distal to the right colon. Histopathological findings were suggestive of ischaemia and mild inflammation. Nine of the 10 patients discontinued BRAF/MEK inhibitors. Drugs were reintroduced in four patients, three of whom had a severe relapse of diarrhoea. Two patients required surgery and underwent intestinal resection. One patient died of enterocolitis.
Conclusion
BRAF/MEK inhibitors can induce severe colitis characterised by ulcerations of the right colon.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Gastroentérologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
- Université Paris Saclay, Le Kremlin Bicêtre, France.
- Centre de Recherche en Épidémiologie et Santé des Populations (CESP, Inserm U1018), Villejuif, France.
- Dermatology Unit, Department of Medicine, Institute Gustave Roussy, Villejuif, France.
- Laboratoire d'Anatomopathologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
- Service de Dermatologie, Hôpitaux Civils de Colmar, Colmar, France.
ORCID-Profile: Franck Carbonnel, Anthony Buisson, Aurélien Amiot, Antoine Meyer, Catherine Dong
Zitieren
APA
Carbonnel, F., Routier, E., Lazure, T., Mussini, C., Bellanger, C., Merklen, C., Bejou, B., Buisson, A., Amiot, A., Meyer, A., Dong, C., & Robert, C. (2023). Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors. Alimentary Pharmacology & Therapeutics, 57(7), 792-799. https://doi.org/10.1111/apt.17352
Vancouver
Carbonnel F, Routier E, Lazure T, Mussini C, Bellanger C, Merklen C, et al. Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors. Alimentary Pharmacology & Therapeutics. 2023;57(7):792-799. doi:10.1111/apt.17352
BibTeX
@article{Carbonnel2023,
author = {Carbonnel, Franck and Routier, Emilie and Lazure, Thierry and Mussini, Charlotte and Bellanger, Christophe and Merklen, Carine and Bejou, Bakhtiar and Buisson, Anthony and Amiot, Aurélien and Meyer, Antoine and Dong, Catherine and Robert, Caroline},
title = {Severe colitis in patients with melanoma treated with BRAF / MEK inhibitors},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {7},
pages = {792--799},
doi = {10.1111/apt.17352}
}
EUVIMED